Miglustat Accord (Miglustat)

Miglustat is employed in substrate reduction therapy targeting lysosomal storage disorders.

• Gaucher disease type 1: reduces glycosphingolipid accumulation, helping to improve hematologic parameters and organ size.
• Niemann‑Pick disease type C: lowers cholesterol and sphingolipid storage, supporting neurological function and disease progression.

• Miglustat inhibits the enzyme glucosylceramide synthase, the first step in the biosynthesis of glycosphingolipids. By blocking this pathway, the drug decreases the production of glucosylceramide and downstream complex sphingolipids, thereby reducing substrate accumulation within lysosomes of affected cells. The reduction in glycosphingolipid synthesis helps to restore cellular homeostasis and mitigate disease‑related pathology.

Miglustat may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Diarrhea: frequent loose stools, often mild to moderate, may lead to dehydration.
• Nausea: sensation of queasiness, may accompany meals and affect appetite.
• Abdominal pain: cramping or discomfort in the stomach area, sometimes intermittent.
• Weight loss: gradual reduction in body weight, usually linked to gastrointestinal effects.
• Flatulence: increased intestinal gas causing bloating.
• Headache: mild to moderate head pain, may be tension‑type.

Serious or Rare Side Effects

• Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain and elevated enzymes.
• Severe allergic reactions: rash, itching, swelling, or anaphylaxis requiring immediate medical attention.
• Elevated liver enzymes: potential indication of hepatic stress, monitored via blood tests.
• Seizures: rare occurrence of convulsive episodes, especially in patients with pre‑existing neurological conditions.
• Depression or mood changes: rare psychiatric effects such as sadness or anxiety.

When prescribing Miglustat, clinicians should consider several safety measures and monitoring requirements.

• Monitor gastrointestinal symptoms: assess severity and manage dehydration if needed.
• Assess liver function: perform baseline and periodic liver enzyme tests.
• Avoid in patients with known hypersensitivity: discontinue if allergic reaction occurs.
• Use caution in renal impairment: adjust dose or monitor renal function closely.
• Pregnancy and lactation: safety not established; discuss potential risks with the patient.
• Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Miglustat can interact with other medicines, affecting its absorption or therapeutic effect.

Major Interactions (Avoid)

• Concomitant use with cholestyramine or other bile‑acid sequestrants: may markedly reduce miglustat absorption.
• Co‑administration with strong intestinal pH modifiers (e.g., high‑dose antacids): can impair drug uptake.

Moderate Interactions (Monitor Closely)

• Warfarin: miglustat may alter INR; monitor coagulation parameters.
• Antidiabetic agents (e.g., insulin, sulfonylureas): increased risk of hypoglycemia; observe blood glucose.
• Other substrate reduction therapies: additive effects on glycosphingolipid synthesis may increase toxicity.
• Antiepileptic drugs: potential changes in plasma levels; adjust dosing if needed.